{"member_organisations": "", "identification_number": "891847325413-63", "fields_of_interest": "Economy, finance and the euro, Culture, International co-operation and development, Education and training, Employment and Social Affairs, Public Health, Digital economy and society", "head_office_address": "Ludger Ltd Culham Science Centre Abingdon", "full_time_equivalent_fte": "2", "person_with_legal_responsibility": "Daryl Fernandes", "inter_groups": "", "financial_year_start_date": "01/01/2016", "grants": "151013", "head_office_country": "United Kingdom", "eu_initiatives": "We will be visiting Luxembourg to have meetings with various EU Institutions and agencies and intend to apply under H2020 Funding to support efforts to build an informatics system to support the development of new precision medicine workflows for people with diabetes.", "organisation_name": "Ludger Ltd (Ludger Ltd)", "belgium_office_post_code": "", "number_of_persons_involved": "6", "procurement": "", "section": "II - In-house lobbyists and trade/business/professional associations", "source": "", "belgium_office_address": "", "subsection": "Companies & groups", "belgium_office_phone": "", "number_of_ep_accredited_persons": "", "overall_budget_turnover_as_a_range": "", "belgium_office_city": "", "persons_accredited_for_access_to_european_parliament_premises": "", "estimate_of_costs_absolute_amount": "", "registration_date": "12/01/2017", "website_address": "http://www.ludger.com", "commission_expert_groups_and_other_similar_entities_european_commission": "NA", "head_office_post_box": "", "head_office_city": "Oxfordshire", "membership": "OBN (http://www.obn.org.uk/) \n \nMediwales (http://www.mediwales.com/) \n \nConsortia (EU-funded programmes and training networks): \nGlySign (http://www.glysign.eu/) \nGlyCoCan (https://glycocan.eu/) \nGlycoPar (http://www.glycopar.eu/) \nIBDBIOM (http://www.ibdbiom.eu/) \nHighGlycan (http://www.highglycan.eu/)", "head_office_post_code": "OX14 3EB", "goals__remit": "Ludger is a UK bioscience SME specialising in glycomics for healthcare. It was founded in 1999 by CEO Dr Daryl Fernandes and has labs at the Culham Science Centre and an office in Shanghai. Our main focus is on patient stratification in inflammatory conditions, cancers and cardiovascular diseases.  \nMain activities: \n 1: Services for biopharma to support regulatory submissions. \n 2: Products for drug development. \n 3: Funded collaborations in medical research. \n 4: Active R&D programme for development of novel glycomics technologies to support biopharmaceutical realisation and Precision Medicine.  \n \nOur main clients are developers and producers of glycoprotein therapeutics. We have sales territories in USA, UK, Europe, India, China, Japan, Korea and Singapore. \n \nWe intend to greatly expand our commercial operations over the next decade.", "industry_forums": "", "head_office_phone": "(+44)1865 408 554", "level_of_interest": "global", "relevant_communication": "Articles & publications: \nhttp://www.ludger.com/research-and-development/articles.php \n \nTalks & presentations: \nhttp://www.ludger.com/research-and-development/presentations.php \n \nPosters: \nhttp://www.ludger.com/research-and-development/posters.php", "financial_year_end_date": "01/12/2016", "estimate_of_costs_as_a_range": "50000-99999", "overall_budget_turnover_absolute_amount": "0", "legal_status": "Private Limited Company (UK Company No 3803367)", "person_in_charge_of_eu_relations": "Christel Gudberg", "customers": "", "belgium_office_post_box": "", "position": "Project and Grant Lead"}